Jason Starr, DO
Hematology & Oncology · Jacksonville, FLNPI 1205090107
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $21,200 of the $30,236 with a category attached, or 70.1%. It is spread thinly across 17 manufacturers, the largest accounting for just 16.3%.
Across 38 payments — averaging $795.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$5K
- Taiho Oncology, Inc.$4K
- Exelixis Inc.$4K
- Tersera Therapeutics LLC$4K
- Jazz Pharmaceuticals Inc.$3K
- Helsinn Therapeutics (U.S.), Inc.$3K
- plus $7K from 11 others
Across 117 payments — averaging $9029.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$662K
- AstraZeneca$145K
- Amgen$74K
- Boehringer Ingelheim$44K
- Daiichi Sankyo Company LTD$33K
- Daiichi Sankyo Inc.$32K
- plus $66K from 8 others
What the payments were for
- Consulting fees$21,20070%
- Speaking & faculty fees$7,94826%
- Food & beverage$1,0764%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 6 | $4,925 |
| Taiho Oncology, Inc. | 2 | $4,338 |
| Exelixis Inc. | 6 | $4,004 |
| Tersera Therapeutics LLC | 5 | $3,974 |
| Jazz Pharmaceuticals Inc. | 1 | $3,296 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $2,655 |
| Array Biopharma Inc | 1 | $2,520 |
| Advanced Accelerator Applications | 1 | $1,485 |
| Boehringer Ingelheim | 1 | $1,480 |
| Novartis | 2 | $1,156 |
| Genentech USA, Inc. | 1 | $125 |
| Lexicon Pharmaceuticals, Inc. | 3 | $107 |
| Bayer | 3 | $80 |
| Foundation Medicine, Inc. | 2 | $28 |
| Tempus AI, Inc | 1 | $28 |
| Deciphera Pharmaceuticals Inc. | 1 | $25 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,236 in reported general payments places this provider in the 75th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TibsovoIvosidenib | 11 | $342,815 |
| Oxycodone Hcl | 20 | $372 |
| Spironolactone | 15 | $101 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Jacksonville
- Edith PerezJacksonville$1.1M
- Vamsidhar VelchetiJacksonville$966K
- Arnab BasuJacksonville$440K
- Sikander AilawadhiJacksonville$179K
- James ForanJacksonville$164K
- Asher Chanan KhanJacksonville$109K
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.